Project Grant R01CA299197
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69M Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 24, 2025, with completion targeted for August 31, 2029. This award supports fundamental research investigating the mechanisms and impact of neuregulin 3 (NRG3) induction in bone metastasis, with the objective of advancing understanding of how breast cancer cells preferentially...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $2.68 million Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, with an award date of August 1, 2025, and a completion date of July 31, 2030. This five-year research initiative, led by Principal Investigator James Manfredi, investigates mutant p53 protein's role in tumorigenesis, invasion, and metastasis. The program comprises four integrated...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $169,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, effective August 1, 2025, through July 31, 2027. This research grant supports a two-year investigation into epigenetic regulation of melanoma-associated fibroblast plasticity, specifically examining how histone variant dysfunction affects the tumor microenvironment (TME). The principal...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This research initiative addresses immune resistance mechanisms in colorectal cancer (CRC), specifically targeting the myeloid-stromal axis that suppresses anti-tumor immunity in microsatellite stable cases resistant to immune checkpoint blockade. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $147,083 Project Grant to Icahn School of Medicine at Mount Sinai under the Cancer Research Manpower program (CFDA 93.398) for the period August 1, 2025 through July 31, 2027. This award supports mentored postdoctoral research training through an NCI Pathway to Independence Award (K99/R00) mechanism, funding a career development project titled "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Weill Medical College of Cornell University a $683,979 Project Grant under the Cancer Biology Research program (CFDA 93.396) for research investigating the role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer. The award, effective June 1, 2025, through April 30, 2030, will deliver fundamental research aimed at understanding how specific molecular features in early, untreated prostate cancer...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $692,197 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2031. The award funds research and development of MTAP (Methylthioadenosine Phosphorylase) transition state analog inhibitors designed to enable synthetic-lethal cancer therapy approaches. The project delivers novel, highly specific MTAP inhibitor compounds and...
- Federal Project Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $434,542 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a Drosophila (fruit fly) model for studying aromatase inhibitor (AI)-induced musculoskeletal pain. The research addresses a significant clinical gap in breast cancer treatment, as approximately 40% of post-menopausal women receiving AI therapy (letrozole, anastrozole, or exemestane)...